Know Labs (KNWN) 10-Q 14 Aug 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jun. 30, 2024	Aug. 14, 2024
Cover [Abstract]
Entity Registrant Name	KNOW LABS, INC.
Entity Central Index Key	0001074828
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding		99,618,897
Entity File Number	000-30262
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	90-0273142
Entity Address Address Line 1	619 Western Avenue
Entity Address Address Line 2	Suite 610
Entity Address City Or Town	Seattle
Entity Address State Or Province	WA
Entity Address Postal Zip Code	98101
City Area Code	206
Local Phone Number	903-1351
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	KNW
Security Exchange Name	NYSE
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2024	Sep. 30, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 2,129,954	$ 8,023,716
Total current assets	2,129,954	8,023,716
PROPERTY AND EQUIPMENT, NET	88,668	81,325
OTHER ASSETS
Other assets	159,244	15,766
Operating lease right-of-use asset	364,342	145,090
TOTAL ASSETS	2,742,208	8,265,897
CURRENT LIABILITIES:
Accounts payable - trade	1,255,888	1,292,861
Accrued expenses	116,666	94,062
Accrued expenses - related parties	99,692	218,334
Current portion of convertible notes payable, net	4,539,818	2,761,931
Current portion of operating lease right-of-use liability	105,653	154,797
Total current liabilities	6,117,717	4,521,985
NON-CURRENT LIABILITIES:
Operating lease liability, net of current portion	280,714	0
Non-current portion of convertible notes payable, net	945,258	0
Total liabilities	7,343,689	4,521,985
Preferred stock - $0.001 par value, 5,000,000 shares authorized, Series C and D shares issued and outstanding as follows:
Common stock - $0.001 par value, 200,000,000 shares authorized, 86,368,897 and 80,358,463 shares issued and outstanding at 6/30/2024 and 9/30/2023, respectively	86,369	80,358
Additional paid in capital	130,360,164	125,501,537
Accumulated deficit	(135,050,819)	(121,840,788)
Total stockholders' (deficit) equity	(4,601,481)	3,743,912
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	2,742,208	8,265,897
Series D Convertible Preferred Shares [Member]
Preferred stock - $0.001 par value, 5,000,000 shares authorized, Series C and D shares issued and outstanding as follows:
Series C Convertible Preferred stock $0.001 par value, 30,000 shares authorized, 17,858 shares issued and outstanding at 6/30/2024 and 9/30/2023, respectively	1,015	1,015
Series C Convertible Preferred Shares [Member]
Preferred stock - $0.001 par value, 5,000,000 shares authorized, Series C and D shares issued and outstanding as follows:
Series C Convertible Preferred stock $0.001 par value, 30,000 shares authorized, 17,858 shares issued and outstanding at 6/30/2024 and 9/30/2023, respectively	$ 1,790	$ 1,790

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2024	Sep. 30, 2023
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	5,000,000	5,000,000
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	200,000,000	200,000,000
Common stock shares issued	86,368,897	80,358,463
Common stock shares outstanding	86,368,897	80,358,463
Convertible Preferred Stock Series C [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	30,000	30,000
Preferred stock shares issued	17,858	17,858
Preferred stock shares outstanding	17,858	17,858
Convertible Preferred Stock Series D [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	20,000	20,000
Preferred stock shares issued	10,161	10,161
Preferred stock shares outstanding	10,161	10,161

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
OPERATING EXPENSES-
RESEARCH AND DEVELOPMENT EXPENSES	$ 1,348,985	$ 1,879,519	$ 5,010,618	$ 6,186,039
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	2,486,846	1,359,782	7,025,503	5,507,511
Total operating expenses	3,835,831	3,239,301	12,036,121	11,693,550
OPERATING LOSS	(3,835,831)	(3,239,301)	(12,036,121)	(11,693,550)
OTHER INCOME (EXPENSE), NET
Interest income	30,619	23,511	126,872	114,325
Interest expense	(298,248)	0	(1,038,499)	(389,626)
Other (expense)	0	(384,137)	0	(384,137)
Total other expense, net	(267,629)	(360,626)	(911,627)	(659,438)
LOSS BEFORE INCOME TAXES	(4,103,460)	(3,599,927)	(12,947,748)	(12,352,988)
Income tax expense	0	0	0	0
NET LOSS	(4,103,460)	(3,599,927)	(12,947,748)	(12,352,988)
Deemed dividends on Series C and D Preferred Stock	(100,045)	(3,337,494)	(262,283)	(3,337,494)
Common stock dividends on Series D Preferred Stock	0	(1,627,230)	0	(1,627,230)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (4,203,505)	$ (8,564,651)	$ (13,210,031)	$ (17,317,712)
Basic and diluted loss per share	$ (0.05)	$ (0.18)	$ (0.16)	$ (0.36)
Weighted average shares of common stock outstanding- basic and diluted	83,038,866	48,928,911	82,314,925	48,604,274

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY (Unaudited) - USD ($)	Total	Series D Convertible Preferred Stock [Member]	Common Stock [Member]	Series C Convertibles Preferred Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Balance, shares at Sep. 30, 2022		10,161	48,156,062	17,858
Balance, amount at Sep. 30, 2022	$ 9,862,613	$ 1,015	$ 48,158	$ 1,790	$ 111,209,388	$ (101,397,738)
Stock compensation expense - employee options	744,640	0	$ 0	0	744,640	0
Issuance of common stock for stock option exercises, shares			1,875
Issuance of common stock for stock option exercises, amount	2,343	0	$ 1	0	2,342	0
Issuance of common stock for exercise of warrants, shares			50,000
Issuance of common stock for exercise of warrants, amount	12,500	0	$ 50	0	12,450	0
Expenses for extension of notes and warrants	206,994	0	0	0	206,994	0
Net loss	(3,822,859)	$ 0	$ 0	$ 0	0	(3,822,859)
Balance, shares at Dec. 31, 2022		10,161	48,207,937	17,858
Balance, amount at Dec. 31, 2022	7,006,231	$ 1,015	$ 48,209	$ 1,790	112,175,814	(105,220,597)
Balance, shares at Sep. 30, 2022		10,161	48,156,062	17,858
Balance, amount at Sep. 30, 2022	9,862,613	$ 1,015	$ 48,158	$ 1,790	111,209,388	(101,397,738)
Net loss	(12,352,988)
Balance, shares at Jun. 30, 2023		10,161	52,358,463	17,858
Balance, amount at Jun. 30, 2023	715,413	$ 1,015	$ 52,358	$ 1,790	119,375,700	(118,715,450)
Balance, shares at Dec. 31, 2022		10,161	48,207,937	17,858
Balance, amount at Dec. 31, 2022	7,006,231	$ 1,015	$ 48,209	$ 1,790	112,175,814	(105,220,597)
Stock compensation expense - employee options	1,182,547	0	0	0	1,182,547	0
Expenses for extension of notes and warrants	142,727	0	0	0	142,727	0
Net loss	(4,930,202)	$ 0	$ 0	$ 0	0	(4,930,202)
Balance, shares at Mar. 31, 2023		10,161	48,207,937	17,858
Balance, amount at Mar. 31, 2023	3,401,303	$ 1,015	$ 48,209	$ 1,790	113,501,088	(110,150,799)
Stock compensation expense - employee options	536,858	0	$ 0	0	536,858	0
Issuance of common stock for stock option exercises, shares			165,015
Issuance of common stock for stock option exercises, amount	2,344	0	$ 165	0	2,179	0
Issuance of common stock for exercise of warrants, shares			2,582,727
Issuance of common stock for exercise of warrants, amount	374,835	0	$ 2,581	0	372,254	0
Net loss	(3,599,927)	0	$ 0	0	0	(3,599,927)
Deemed dividends on Series C and D Preferred Stock, shares			1,402,784
Deemed dividends on Series C and D Preferred Stock, amount	0	0	$ 1,403	0	1,625,827	(1,627,230)
Deemed dividends on Series C and D Preferred Stock	0	$ 0	$ 0	$ 0	3,337,494	3,337,494
Balance, shares at Jun. 30, 2023		10,161	52,358,463	17,858
Balance, amount at Jun. 30, 2023	715,413	$ 1,015	$ 52,358	$ 1,790	119,375,700	(118,715,450)
Balance, shares at Sep. 30, 2023		10,161	80,358,463	17,858
Balance, amount at Sep. 30, 2023	3,743,912	$ 1,015	$ 80,358	$ 1,790	125,501,537	(121,840,788)
Stock compensation expense - employee options	699,246	0	0	0	699,246	0
Net loss	(3,446,624)	0	0	0	0	(3,446,624)
Deemed dividends on Series C and D Preferred Stock	0	0	$ 0	0	63,629	63,629
Issuance of common stock for services, shares			105,000
Issuance of common stock for services, amount	26,250	0	$ 105	0	26,145	0
Isssuance of common stock for common stock offering, shares			883,061
Isssuance of common stock for common stock offering, amount	203,105	$ 0	$ 884	$ 0	202,221	0
Balance, shares at Dec. 31, 2023		10,161	81,346,524	17,858
Balance, amount at Dec. 31, 2023	1,225,889	$ 1,015	$ 81,347	$ 1,790	126,492,778	(125,351,041)
Balance, shares at Sep. 30, 2023		10,161	80,358,463	17,858
Balance, amount at Sep. 30, 2023	$ 3,743,912	$ 1,015	$ 80,358	$ 1,790	125,501,537	(121,840,788)
Issuance of common stock for stock option exercises, shares	823,328
Net loss	$ (12,947,748)
Balance, shares at Jun. 30, 2024		10,161	86,368,897	17,858
Balance, amount at Jun. 30, 2024	(4,601,481)	$ 1,015	$ 86,369	$ 1,790	130,360,164	(135,050,819)
Balance, shares at Dec. 31, 2023		10,161	81,346,524	17,858
Balance, amount at Dec. 31, 2023	1,225,889	$ 1,015	$ 81,347	$ 1,790	126,492,778	(125,351,041)
Stock compensation expense - employee options	616,317	0	$ 0	0	616,317	0
Issuance of common stock for exercise of warrants, shares			714,848
Issuance of common stock for exercise of warrants, amount	0	0	$ 715	0	(715)	0
Expenses for extension of notes and warrants	594,761	0	0	0	594,761	0
Net loss	(5,397,664)	0	0	0	0	(5,397,664)
Deemed dividends on Series C and D Preferred Stock	0	0	$ 0	0	98,609	98,609
Issuance of common stock for services, shares			348,492
Issuance of common stock for services, amount	170,760	0	$ 347	0	170,413	0
Issuance of shares and warrants in connection with debt offering, shares			102,302
Issuance of shares and warrants in connection with debt offering, amount	1,035,963	$ 0	$ 103	$ 0	1,035,860	0
Balance, shares at Mar. 31, 2024		10,161	82,512,166	17,858
Balance, amount at Mar. 31, 2024	(1,753,974)	$ 1,015	$ 82,512	$ 1,790	129,008,023	(130,847,314)
Stock compensation expense - employee options	1,015,953	0	$ 0	0	1,015,953	0
Issuance of common stock for exercise of warrants, shares			108,500
Issuance of common stock for exercise of warrants, amount	0	0	$ 108	0	(108)	0
Net loss	(4,103,460)	0	0	0	0	(4,103,460)
Deemed dividends on Series C and D Preferred Stock	0	0	$ 0	0	100,045	100,045
Common stock dividends on Series C and D Preferred Stock, shares			3,201,534
Common stock dividends on Series C and D Preferred Stock, amount	0	0	$ 3,202	0	(3,202)	0
Issuance of common stock for debt payment, shares			546,697
Issuance of common stock for debt payment, amount	240,000	$ 0	$ 547	$ 0	239,453	0
Balance, shares at Jun. 30, 2024		10,161	86,368,897	17,858
Balance, amount at Jun. 30, 2024	$ (4,601,481)	$ 1,015	$ 86,369	$ 1,790	$ 130,360,164	$ (135,050,819)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,947,748)	$ (12,352,988)
Adjustments to reconcile net loss to net cash (used in) operating activities
Depreciation and amortization	59,009	259,541
Stock based compensation - stock option grants	2,331,516	2,464,045
Issuance of common stock for services	277,010	0
Loss on disposal of assets	0	384,137
Amortization of operating lease right-of-use asset	162,647	96,161
Amortization of debt issuance costs	375,859	0
Interest expense for extension of notes and warrants	594,761	349,721
Changes in operating assets and liabilities:
Other long-term assets	(143,478)	(1,999)
Operating lease right-of-use liability	(150,329)	(99,803)
Accounts payable - trade and accrued expenses	(133,011)	(74,866)
NET CASH (USED IN) OPERATING ACTIVITIES	(9,573,764)	(8,976,051)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of research and development equipment	(66,352)	(80,798)
NET CASH (USED IN) INVESTING ACTIVITIES:	(66,352)	(80,798)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt offering	3,805,699	0
Proceeds from issuance of common stock offering, net	203,105	0
Payments for debt offering	(262,450)	0
Proceeds from issuance of common stock for stock options exercise	0	4,687
Proceeds from issuance of common stock for warrant exercise	0	387,335
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,746,354	392,022
NET (DECREASE) IN CASH AND CASH EQUIVALENTS	(5,893,762)	(8,664,827)
CASH AND CASH EQUIVALENTS, beginning of period	8,023,716	12,593,692
CASH AND CASH EQUIVALENTS, end of period	2,129,954	3,928,865
Supplemental disclosure of non-cash financing activity:
Deemed dividends on Series C and D Preferred Stock	262,283	3,337,494
Common stock dividends on Series D Preferred Stock	0	1,627,230
Warrants issued for debt offering	1,536,743	0
Common stock issued for debt payment	$ 240,000	$ 0

ORGANIZATION

ORGANIZATION	9 Months Ended
	Jun. 30, 2024
ORGANIZATION
ORGANIZATION	1. ORGANIZATION Know Labs, Inc. (the “Company”) was incorporated under the laws of the State of Nevada in 1998. The Company currently has authorized 205,000,000 shares of capital stock, of which 200,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share. The Company is focused on the development and commercialization of our proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with our machine learning platform, our technology is capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify, and measure the unique “signature” of said materials or analytes. The first application of our sensor technology is in a product to non-invasively monitor blood glucose levels. Our device will provide the user with real-time information on their blood glucose levels. We launched the Generation 2 working prototype device during the three months ended March 31, 2024. This device embodies the sensor which has been used in internal clinical testing. The device, which is a wearable format and may be a final form factor, ready for commercialization. That device will be utilized in expanded internal and external testing. The device may be refined over time and will require FDA clearance prior to entering the market.

LIQUIDITY AND GOING CONCERN

LIQUIDITY AND GOING CONCERN	9 Months Ended
	Jun. 30, 2024
LIQUIDITY AND GOING CONCERN
LIQUIDITY AND GOING CONCERN	2. LIQUIDITY AND GOING CONCERN The Company has cash and cash equivalents of $2,129,954 and a net working capital deficit of $3,987,763 of as of June 30, 2024. The Company anticipates that it will record losses from operations for the foreseeable future. The Company’s ability to transition profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure. The Company believes that it has enough available cash and flexibility with its operating expenses to operate until October 31, 2024. On February 27, 2024, the Company (a) entered into a securities purchase agreement with the selling stockholder pursuant to which we may issue to the selling stockholder one or more senior convertible notes in the aggregate principal amount of up $14,400,000 for an aggregate purchase price equal to up to $12,000,000 and common stock purchase warrants and (b) issued a $4,800,000 Note and the warrant to the selling stockholder in exchange for a purchase price of $4,000,000 and net proceeds of $3,805,699. See Note 6. On March 20, 2024, the Company entered into an At the Market Offering Agreement with The Benchmark Company, LLC pursuant to which we may, from time to time, offer and sell shares of our common stock through or to The Benchmark Company, LLC as the Company’s sales agent or manager in an aggregate amount of up to $5,000,000. The Company has not received any funds under this agreement as of June 30, 2024. The proceeds of warrants currently outstanding, to the extent not exercised on a cashless basis, may generate potential proceeds. We cannot provide assurance that any of these warrants will be exercised. Management of the Company intends to raise additional funds through the issuance of equity securities or debt. The Company is currently working on some capital fund raising transactions. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. As a result, the substantial doubt about the Company’s ability to continue as a going concern has not been alleviated. The accompanying consolidated financial statements do not include any adjustments that may be necessary if the Company is unable to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS	9 Months Ended
	Jun. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS
SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS	3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS Basis of Presentation Principles of Consolidation Cash and Cash Equivalents Property and Equipment Long-Lived Assets Revenue Recognition · identification of the contract, or contracts, with the customer; · identification of the performance obligations in the contract; · determination of the transaction price; · allocation of the transaction price to the performance obligations in the contract; and · recognition of the revenue when, or as, the Company satisfies a performance obligation. Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Research and Development Expenses Advertising Fair Value Measurements and Financial Instruments Fair Value Measurement and Disclosures Level 1 – Quoted prices in active markets for identical assets and liabilities; Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of June 30, 2024 and 2023 are based upon the short-term nature of the assets and liabilities. The fair value of the Company’s convertible notes payable are not readily available given the terms and conditions, including the conversion features, are complex. The Company has a money market account which is considered a Level 1 asset. The balance as of June 30, 2024 and September 30, 2023 was $2,103,240 and $7,836,393, respectively. No other assets or liabilities are required to be recorded at fair value on a recurring nature. Derivative Financial Instruments – The Company determined that the conversion features for purposes of bifurcation within its currently outstanding convertible notes payable were immaterial and there was no derivative liability to be recorded as of June 30, 2024 and 2023. Stock Based Compensation Convertible Securities Net Loss per Share As of June 30, 2024, the Company had 86,368,897 shares of common stock issued and outstanding. As of June 30, 2024, there were options outstanding for the purchase of 30,072,106 shares of the Company’s common stock (including unearned stock option grants totaling 4,179,825 shares related to performance targets), warrants for the purchase of 25,816,476 shares of the Company’s common stock, 8,108,356 shares of the Company’s common stock issuable, collectively, upon the conversion of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and approximately 319,121 shares of the Company’s common stock, collectively, reserved to pay accrued dividends on our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 shares of its common stock at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,761,931 and 4,572,000 shares of its common stock at the current price of $1.00 per share reserved and are issuable upon conversion of convertible debentures of $4,572,000. Further, under the current terms of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and assuming no changes in the ownership thereof, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the June 30, 2024, calculation of net loss per share because the impact is antidilutive. As of June 30, 2023, the Company had 52,358,463 shares of common stock issued and outstanding. As of June 30, 2023, there were options outstanding for the purchase of 14,506,158 common shares (including unearned stock option grants totaling 3,869,825 shares related to performance targets), warrants for the purchase of 18,856,313 common shares, 8,108,356 shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock and approximately 2,920,000 of common shares reserved to pay Series C and D Convertible Preferred Stock dividends. In addition, the Company currently has 9,020,264 common shares at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,255,066. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the June 30, 2023, calculation of net loss per share because their impact is antidilutive. Comprehensive loss Dividend Policy Use of Estimates Recent Accounting Pronouncements Based on the Company’s review of accounting standard updates recently issued, those standards not yet required to be adopted and proposed standards for the future, the Company does not believe such items are expected to have a significant impact on the Company’s consolidated financial statements.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Jun. 30, 2024
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT Property and equipment as of June 30, 2024 and September 30, 2023 was comprised of the following: Estimated Useful Lives June 30, 2024 September 30, 2023 Machinery and equipment 2-3 years $ 279,683 $ 213,330 Furniture and fixtures 3 years 21,366 21,366 Less: accumulated depreciation (212,381 ) (153,371 ) $ 88,668 $ 81,325 Total depreciation expense was $59,009 and $259,541 for the nine months ended June 30, 2024 and 2023, respectively. Equipment is used primarily for research and development purposes and accordingly $57,092 and $246,563 in depreciation is classified in research and development expenses during the nine months ended June 30, 2024 and 2023, respectively.

LEASES

LEASES	9 Months Ended
	Jun. 30, 2024
LEASES
LEASES	5. LEASES The Company has entered into operating leases for office and development facilities which range from two to three years and include options to renew. The Company determines whether an arrangement is or contains a lease based upon the unique facts and circumstances at the inception of the lease. Operating lease liabilities and their corresponding right-of-use asses are recorded based upon the present value of the lease payments over the expected lease term. As of June 30, 2024 and September 30, 2023, total operating lease liabilities were approximately $386,367 and $154,797, respectively. Right of use assets totaled approximately $364,342 and $145,090 at June 30, 2024 and September 30, 2023, respectively. In the nine months ended June 30, 2024 and 2023, the Company recognized $120,000 and $203,000, respectively in total lease costs for the leases. Because the rate implicit in each lease is not readily determinable, the Company uses its estimated incremental borrowing rate to determine the present value of the lease payments. The weighted average remaining lease term for the operating leases was 37 months at June 30, 2024 and the weighted average discount rate was 7%. The minimum future lease payments as of June 30, 2024 are as follows: Year Ended June 30, 2025 $ 126,760 2026 142,755 2027 147,282 2028 12,682 Total remaining payments 429,478 Less imputed interest (43,111 ) Total lease liability $ 386,367

CONVERTIBLE NOTES PAYABLE AND N

CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE	9 Months Ended
	Jun. 30, 2024
CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE
CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE	6. CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE Convertible notes payable as of June 30, 2024 and September 30, 2023 are summarized below: June 30, 2024 September 30, 2023 Convertible note- Clayton A. Struve $ 1,301,005 $ 1,301,005 Convertible note- Ronald P. Erickson and affiliates 1,460,926 1,460,926 Lind Global Fund II LP 2,723,145 - $ 5,485,076 $ 2,761,931 Long term $ 945,258 $ - Short term 4,539,818 2,761,931 $ 5,485,076 $ 2,761,931 Convertible Promissory Notes with Clayton A. Struve The Company owes Clayton A. Struve, a significant stockholder, $1,301,005 under convertible promissory or OID notes. The Company recorded accrued interest of $99,692 and $94,062 as of June 30, 2024 and September 30, 2023, respectively. On September 15, 2023, the due dates on the notes was further extended to September 30, 2024. The Company expensed $230,005 as loss on debt extinguishment during the year ended September 30, 2023 related to the extension of the notes. The Company recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable. The extension value will be reclassified to equity upon conversion. Convertible Redeemable Promissory Notes with J3E2A2Z The Company owes Ronald P. Erickson and J3E2A2Z, an entity affiliated controlled by Ronald P. Erickson $1,460,926 under convertible promissory notes. On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of our for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. The Company recorded accrued interest of $116,666 and $218,334 as of June 30, 2024 and September 30, 2023, respectively. On September 15, 2023, the due dates on the notes were extended to September 30, 2024. The Company expensed $276,860 as interest during the year ended September 30, 2023 related to the extension of the notes. The Company recorded in convertible note payable the incremental value related to the conversion feature and as such, we recorded the extension value as an expense with an offset to convertible note payable. The extension value will be amortized to equity upon conversion. Senior Convertible Note with Lind Global Fund II, LP On February 27, 2024, the Company (a) entered into a Securities Purchase Agreement with Lind Global Fund II, LP (“Lind”), pursuant to which the Company may issue Lind one or more senior convertible notes (the “Notes”) in the aggregate principal amount of up to Fourteen Million Four Hundred Thousand Dollars ($14,400,000) for an aggregate purchase price equal to up to Twelve Million Dollars ($12,000,000) (the “Offering”) and Common Stock purchase warrants and (b) issued to Lind an initial Note with an outstanding principal amount of Four Million Eight Hundred Thousand Dollars ($4,800,000) in exchange for a purchase price of Four Million Dollars ($4,000,000), that is convertible into shares of the Company’s common stock at an initial conversion price of $1.00 per share, subject to adjustment, and an initial Warrant to purchase up to 6,000,000 shares of the Company’s common stock at an initial exercise price of $0.80 per share, subject to adjustment. Warrant Shares issued shall be equal to the applicable funding amount multiplied by 75% and divided by the volume weighted average price of the common stock on the trading date immediately preceding the closing date. The Company issued 3,000,000 to Lind in connection with the $4,000,000 funding amounts. The Notes bearing $800,000 Original Issue Discount (the “OID”) do not carry any interest. Beginning on the date that is 120 days from the issuance date of each Note and on each one (1) month anniversary thereafter for 20 months, the Company shall pay Lind an amount equal to the greater of (x) 5% of the aggregate principal amount of such Note or (y) $240,000, until the outstanding principal amount of such Note has been paid in full prior to or on its maturity date or, if earlier, upon acceleration, conversion or redemption of such Note in accordance with the terms thereof (the “Monthly Payments”). At the Company’s discretion, the Monthly Payments shall be made in (i) cash, (ii) shares of the Company’s common stock, or (iii) a combination of cash and shares; if made in shares, the number of shares shall be determined by dividing (x) the principal amount being paid in shares by (y) 90% of the average of the 3 lowest daily VWAPs during the 20 trading days prior to the applicable payment date. The Notes set forth certain conditions that must be satisfied before the Company may make any Monthly Payments in shares of common stock. If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of 5% of such Monthly Payment. Lind may elect with respect to no more than two (2) Monthly Payments to increase the amount of such monthly payment up to $750,000 which increase would be paid only in shares of the Company’s common stock upon notice to the Company. Any such increased payment shall be deducted from the amount of the last monthly payment owed under this Note. Issuance of Note Shares and Warrant Shares upon repayment or conversion of Notes and exercise of Warrants is subject to an ownership limitation equal to 4.99% of the Company’s outstanding shares of common stock; provided, that if Lind and its affiliates beneficially own in excess of 4.99% of the Company’s outstanding shares of common stock, then such limitation shall automatically increase to 9.99% so long as Lind and its affiliates own in excess of 4.99% of such common stock (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon Lind and its affiliates ceasing to own in excess of 4.99% of such common stock). Upon the occurrence of any Event of Default, the Notes will become immediately due and payable and the Company must pay Lind an amount equal to 120% of the then outstanding principal amount of each Note, in addition to any other remedies under the Note or the other Transaction Documents. Events of default include, among others, failure of the Company to make any Note payment when due, a default in any indebtedness or adverse judgements in excess of $250,000, the failure of the Company to instruct its transfer agent to issue unlegended certificates, the Company’s shares of common stock no longer being public traded or listed on a national securities exchange, any stop order or trading suspension restricting the trading in the Company’s common stock, and the Company’s market capitalization is below $15 million for consecutive 10 days. The Warrant may be exercised via cashless exercise in the event there is no effective registration statement covering the shares of Common Stock underlying a Warrant exercise. Pursuant to the terms of the Securities Purchase Agreement, if at any time prior to a date that is 24 months following the closing of the Offering, the Company proposes to offer or sell any additional securities in a subsequent financing, the Company shall first offer Lind the opportunity to purchase up to 20% of such new securities. The Company’s obligations under the Notes are secured by a first-priority security interest in all of its assets pursuant to the terms of a Security Agreement in favor of Lind. In addition, in connection with the Offering, the Company’s subsidiary Particle, Inc., a Nevada corporation (“Particle”), has guaranteed all of the obligations of the Company in connection with the Offering pursuant to the terms of a Guaranty in favor of Lind. The sale of the Notes and the terms of the Offering, including the Guaranty are set forth in the Securities Purchase Agreement, the Note, the Warrant, a Security Agreement, and Guaranty are the Transaction Documents. Pursuant to the Securities Purchase Agreement, the Company registered all of the Note Shares and Warrant Shares issued to Lind in the Offering. The Company received net proceeds of $3,805,699 in exchange for the issuance of the $4,800,000 Notes and 3,000,000 Warrant Shares. The fair value of the 3,000,000 Warrant Shares was $1,536,743 on the date of issuance and was classified in equity. The value of the Warrant Shares was recorded as debt discount (with an offset to APIC) and will be amortized over the two-year term of the Notes. In connection with this Securities Purchase Agreement, the Company incurred approximately $994,000 of issuance costs of which $675,971 were allocated to the Note and $318,330 to the Warrant Shares. The amount allocated to the Notes was recorded as debt discount (with an offset to APIC) and is being amortized over the two-year term of the Notes. The Company recorded $275,830 and $375,859 of amortization of debt issuance costs during the three and nine months ended June 30, 2024 related to this security purchase agreement.

EQUITY

EQUITY	9 Months Ended
	Jun. 30, 2024
EQUITY
EQUITY	7. EQUITY The following description summarizes important terms of the classes of our capital stock as of June 30, 2024. Authorized Capital Stock · 200,000,000 shares of common stock, par value $0.001 per share; and · 5,000,000 shares of “blank check” preferred stock, par value $0.001 per share, of which: · 30,000 shares have been designated as our Series C Convertible Preferred Stock, $0.001 par value per share; and · 20,000 shares have been designated as our Series D Convertible Preferred Stock, 0.001 par value per share. Outstanding Shares of Capital Stock · 86,368,897 shares of common stock issued and outstanding, held by holders of record; · 17,858 shares of Series C Convertible Preferred Stock issued and outstanding, held by one holder of record; and · 10,161 shares of Series D Convertible Preferred Stock issued and outstanding, held by one holder of record. Securities Subject to Price Adjustments If in the future, the Company sells its common stock at a price below $0.25 per share, the conversion price of our outstanding shares of Series C and D convertible preferred stock would adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of the convertible promissory notes referred to above and the exercise price of certain outstanding warrants to purchase 9,020,264 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments. Series C and D Convertible Preferred Stock, Warrants and Dividends On August 5, 2016, the Company closed a Series C Convertible Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a cumulative dividend of 8% and an ownership blocker of 4.99%. Dividends are due and payable in cash when declared by the Company or when the stock is converted. Series C Convertible Preferred stock is senior to Series D Convertible Preferred stock and is entitled to receive equal dividends paid to Series D. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share. On August 14, 2017, the price of the Series C Convertible Preferred Stock and warrant and its conversion price, were adjusted to $0.25 per share pursuant to the documents governing such instruments. As of June 30, 2024, Mr. Struve owns all of the 17,858 issued and outstanding shares of Series C Convertible Preferred Stock. Each holder of Preferred Series C is allowed to vote as a common shareholder as if the shares were converted to common stock up to the ownership blocker of 4.99%. In 2017 the Company closed a $750,000 Series D Convertible Preferred Stock and Warrant offering with Mr. Struve. As of June 30, 2024, Mr. Struve owns all of the 10,161 issued and outstanding shares of Series D Convertible Preferred Stock. Each outstanding share of Series D Convertible Preferred Stock will accrue cumulative cash dividends at a rate equal to 8.0% per annum, subject to adjustment as provided in the Series D Convertible Preferred Stock certificate of designations. Dividends are due and payable in cash when declared by the Company or when the stock is converted. In addition, On August 14, 2017, the price of the Series D Convertible Preferred Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. Each holder of Preferred Series D is allowed to vote as a common shareholder as if the shares were converted to common stock up to the ownership blocker of 4.99%. Based upon the modified terms and conditions of our Series C and D Convertible Preferred Stock certificates of designations dated August 10, 2023, it was determined that Series C and D Convertible Preferred Stock dividends need to be accreted going forward. As of June 30, 2024, cumulative unpaid Series C and D Convertible Preferred Stock dividends totaled approximately $80,000, which on a converted-to-common-stock basis represents approximately 319,121 shares of common stock. The Company has recorded $80,000 in cumulative deemed dividends related to Series C and D Convertible Preferred Stock which have not been paid, net of (i) $350,696 of accumulated dividends with respect to the Series D Convertible Preferred Stock that were settled for 1,402,784 shares of common stock on June 28, 2023 and (ii) $800,384 of accumulated dividends with respect to the Series C and D Convertible Preferred Stock that were settled for 3,201,534 shares of common stock on June 18, 2024. Mr. Struve is subject to an ownership blocker limiting his ownership to 4.99% of our outstanding shares of common stock and thus the number of common shares he can receive for dividends. Unpaid accreted stock dividends will be issued to Mr. Struve if he converts preferred stock or if the Board declares a dividend thereon, limited to his 4.99% ownership blocker. Assuming no changes in the amount of outstanding Series C Convertible Preferred Stock or Series D Convertible Preferred Stock ownership, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock. Common Stock Each share of common stock entitles its holder to one vote on each matter submitted to the stockholders for a vote, and no cumulative voting for directors is permitted. Stockholders do not have any preemptive rights to acquire additional securities issued by the Company. Nine Months Ended June 30, 2024 During the nine months ended June 30, 2024, we had the following sales of unregistered sales of equity securities: The Company issued 453,492 shares of our common stock total to six directors at $0.434 per share for director services for a total value of $196,816 which was expensed during the quarter ended March 31, 2024. On October 26, 2023, the Company closed an offering of its common stock pursuant to which we sold 883,061 shares of common stock, at a purchase price of $0.25 per share. After deducting underwriting commissions and other offering expenses, the Company received net proceeds of $203,105. On March 7, 2024, the Company issued 102,302 shares of the Company’s common stock at $0.782 with a total value of $80,000 per share related to a debt offering. The $80,000 was recorded as debt issuance costs and is being amortized over the two-year term of the debt. On March 8, 2024, the Company issued 714,828 shares of the Company’s common stock in a cashless warrant exercise. On May 24, 2024, the Company issued 108,500 shares of its common stock related to 108,500 warrants exercised at $0.25 per share. On June 18, 2024, Mr. Struve converted dividends of $800,384 into 3,201, shares of our common stock related to the conversion of Series C and D Convertible Preferred Stock. On June 27, 2024, the Company issued 546,697 shares of our common stock at $0.44 per share related to a principal payment of convertible debt settled with a common stock issuance for a total value of $240,000. Warrants to Purchase Common Stock Nine Months Ended June 30, 2024 On September 29, 2023, pursuant to the Underwriting Agreement, the Company issued common stock purchase warrants to Boustead Securities, LLC and The Benchmark Company, LLC to purchase an aggregate of 123,648 shares of Common Stock at an exercise price of $0.25 per share, subject to adjustments. The Representatives’ Warrants are immediately exercisable, and may be exercised at any time and from time to time, in whole or in part, until September 26, 2028 and may be exercised on a cashless basis. The Representatives’ Warrants also include customary anti-dilution provisions and immediate piggyback registration rights with respect to the registration of the shares underlying the Representatives’ Warrants. The warrants were valued at $20,896 and recorded in additional paid in capital as costs from common stock offering. On February 27, 2024, the Company (a) entered into a securities purchase agreement with Lind Global Fund II, LP (“Lind”), issued a Warrant to purchase up to 6,000,000 shares of the Company’s common stock at an initial exercise price of $0.80 per share, subject to adjustment. The Warrant may be exercised via cashless exercise in the event there is no effective registration statement covering the shares of Common Stock underlying a Warrant exercise. The initial 300,000 warrants issued were valued at $1,536,743 and recorded as debt issuance costs (with an offset to additional paid in capital) and is being amortized over the two-year term of the Notes as a component of interest expense. On March 8, 2024, the Company issued 714,828 shares of the Company’s common stock in a cashless warrant exercise. On May 24, 2024, the Company issued 108,500 shares of the Company’s common stock in a cashless warrant exercise. Warrants to purchase 350,157 shares of common stock at $0.42 per share were forfeited. A summary of the warrants outstanding as of June 30, 2024 were as follows: Weighted Average Exercise Shares Price Outstanding October 1, 2023 20,866,313 $ 1.06 Issued 6,123,648 0.79 Exercised (823,328 ) (0.25 ) Forfeited (350,157 ) (0.42 ) Expired - - Outstanding at end of period 25,816,476 $ 1.03 The following table summarizes information about warrants outstanding and exercisable as of June 30, 2024: Weighted Weighted Average Average Number of Remaining Exercise Shares Warrants Life ( In Years) Price Exercisable 8,619,544 1.54 $ 0.25 8,619,544 6,000,000 4.67 0.80 6,000,000 6,512,207 1.48 1.20-1.85 6,512,207 4,684,725 1.85 2.00-3.00 4,684,725 25,816,476 2.21 $ 1.03 25,816,476 The significant weighted average assumptions relating to the valuation of the Company’s warrants for the nine months ended June 30, 2024 were as follows: Assumptions Dividend yield 0% Expected life 3 years Expected volatility 105% Risk free interest rate 4.32% There were warrants of 25,816,476 shares with an aggregate intrinsic value of $1,982,495.

STOCK INCENTIVE PLANS

STOCK INCENTIVE PLANS	9 Months Ended
	Jun. 30, 2024
STOCK INCENTIVE PLANS
STOCK INCENTIVE PLANS	8. STOCK INCENTIVE PLANS On August 12, 2021, the Company established its 2021 Equity Incentive Plan (the “2021 Plan”), which was adopted by stockholders on October 15, 2021. The Company initially had 20,000,000 shares of its common stock authorized as the maximum number of shares of common stock that may be delivered to participants under the 2021 Plan, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. This number was increased to 22,000,000 shares of common stock as of January 1, 2022 as a result of the automatic share reserve increase described below. Nine Months Ended June 30, 2024 During the nine months ended June 30, 2024, the Company issued stock option grants to 32 directors, employees and consultants for 17,410,548 shares at an average exercise price of $0.31 per share. The stock option grants expire in five years. The stock option grants primarily vest immediately to quarterly over two to four years. During the nine months ended June 30, 2024, stock option grants for 1,844,600 shares at an average exercise price of $1.53 per share were forfeited. Stock option activity for the nine months ended June 30, 2024 and the year ended September 30, 2023 was as follows: Weighted Average Options Exercise Price Outstanding as of September 30, 2023 14,506,158 $ 1.55 Granted 17,410,548 0.31 Exercised - - Forfeitures (1,844,600 ) (1.53 ) Outstanding as of June 30, 2024 30,072,106 $ 0.83 The following table summarizes information about stock options outstanding and exercisable as of June 30, 2024: Weighted Weighted Weighted Average Average Average Range of Number Remaining Life Exercise Price Number Exercise Price Exercise Prices Outstanding In Years Outstanding Exercisable Exercisable $0.25-0.51 16,340,548 4.28 $ 0.29 5,531,545 $ 0.34 $0.62 1,050,000 4.89 0.62 - - $0.88-1.25 2,161,875 2.41 0.15 2,013,125 0.40 $1.28 - 1.67 8,379,683 2.94 1.49 2,444,858 1.47 $1.79-3.67 2,140,000 2.54 2.19 1,093,125 2.16 30,072,106 3.70 $ 0.83 11,082,653 $ 0.72 The significant weighted average assumptions relating to the valuation of the Company’s stock option grants for the nine months ended June 30, 2024 were as follows: Assumptions Dividend yield 0% Expected life 3 years Expected volatility 105% Risk free interest rate 4.16-4.64% There are stock option grants of 30,072,106 shares as of June 30, 2024 with an aggregate intrinsic value of $2,524,513. There are 30,072,106 (including unearned stock option grants totaling 4,179,825 shares related to performance milestones) options to purchase common stock at an average exercise price of $0.83 per share outstanding as of June 30, 2024 under the 2021 Plan. The Company recorded $2,331,516 and $2,464,045 of compensation expense, net of related tax effects, relative to stock options for the nine months ended June 30, 2024 and 2023, respectively, in accordance with ASC 718. As of June 30, 2024, there is $5,836,061 of total unrecognized costs related to employee granted stock options that are not vested. These costs are expected to be recognized over a period of approximately 3.7 years.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Jun. 30, 2024
INCOME TAXES
INCOME TAXES	9. INCOME TAXES The Company recorded a provision for income taxes of $0 for the nine months ended June 30, 2024 and 2023. The Company’s effective tax rate was 0% for the nine months ended June 30, 2024 and 2023. The difference between the effective tax rate and the federal statutory tax rate primarily relates to the valuation allowance on the Company’s net operating loss deferred tax asset. For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. As of June 30, 2024 and 2023, the Company retains a full valuation allowance on its deferred tax assets. The realization of the Company’s deferred tax assets depends primarily on its ability to generate taxable income in future periods. The amount of deferred tax assets considered realizable in future periods may change as management continues to reassess the underlying factors it uses in estimating future taxable income.

SIGNIFICANT AND OTHER TRANSACTI

SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES	9 Months Ended
	Jun. 30, 2024
SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES
SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES	10. SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES Transactions with Clayton Struve See Notes 6 and 7 for related party transactions with Clayton A. Struve, a significant stockholder. Related Party Transactions with Ronald P. Erickson See Notes 6, 7 and 11 for related party transactions with Ronald P. Erickson, the Company’s Chairman and Chief Executive Officer and affiliated entities. On October 10, 2023, the Company issued a stock option grant to Ronald P. Erickson for 4,640,844 shares at an exercise price of $0.25 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. Related Party Transactions with Peter J. Conley, Chief Financial Officer and Senior Vice President, Intellectual Property On October 10, 2023, the Company issued a stock option grant to Peter J. Conley for 3,001,000 shares at an exercise price of $0.25 per share. The stock option grant expires in five years. The stock option grant vests quarterly over four years. Related Party Transactions with Directors During the nine months ended June 30, 2024, the Company issued stock option grants to six directors for a total of 2,809,817 shares at an average exercise price of $0.46 per share. The stock option grants expire in five years. The stock option grants vested at issuance.

COMMITMENTS CONTINGENCIES AND L

COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS	9 Months Ended
	Jun. 30, 2024
COMMITMENTS AND CONTINGENCIES (Note 11)
COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS	11. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS Legal Proceedings The Company may from time to time become a party to various legal proceedings arising in the ordinary course of business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to the Company’s business. Employment and Related Agreements Employment Agreement with Ronald P. Erickson, Chairman of the Board and Chief Executive Officer See the Employment Agreement for Ronald P. Erickson that was disclosed in Form 10-K filed with the SEC on December 19, 2023. Mr. Erickson was appointed Chief Executive Officer on January 23, 2023. Employment Agreement with Peter J. Conley, Chief Financial Officer and Senior Vice President, Intellectual Property See the Employment Agreement for Peter J. Conley that was disclosed in Form 10-K filed with the SEC on December 19, 2023. Properties and Operating Leases The Company is obligated under the following leases for its various facilities. On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the current net monthly payment is $2,908. The Company vacated the office on May 31, 2024. On May 18, 2021, the Company entered into a lease for its lab facilities located at 914 E Pine Street, Suite 212, Seattle, WA 98122 and leased 2,642 square feet. The net monthly lease payment was $8,697 and the lease was terminated on February 5, 2024. On October 11, 2021, the Company entered into the First Amendment of Lease and added 2,485 square feet for $5,000 per month. On September 20, 2022, the Company entered into the Second Amendment of Lease for additional space. The expanded space was utilized for research and testing. The Amendment of Lease expired on December 31, 2023. On November 22, 2022, the Company leased an additional 1,800 square feet of lab facilities at 123 Boylston Ave, Suite C, Seattle, WA 98102 with a net monthly payment is $2,250. The Company expects to vacate the office on May 31, 2024. On March 2, 2024, the Company entered into a lease for executive and research and testing facilities at 619 Western Avenue, Suite 610, Seattle, Washington 98104. The Company leases 5,996 square feet and the current net monthly payment is $11,492 and increases at 3% annually after year one. The lease commenced on May 1, 2024 and terminates on July 31, 2027.

SEGMENT REPORTING

SEGMENT REPORTING	9 Months Ended
	Jun. 30, 2024
SEGMENT REPORTING
SEGMENT REPORTING	12. SEGMENT REPORTING The Company considers the business to currently have one operating segment; the development of its radio frequency spectroscopy technology with a first focus on non-invasively ascertaining blood glucose levels.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jun. 30, 2024
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company evaluated subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements were issued. Subsequent to June 30, 2024, the Company had the following material transaction that requires disclosure: On August 7, 2024, the “Company entered into an Underwriting Agreement with Boustead Securities, LLC and The Benchmark Company, LLC, as representatives of the underwriters named therein, relating to the Company’s registered public offering of 13,250,000 units consisting of one share of the Company’s common stock, par value $0.001 per share, and one warrant to purchase one share of Common Stock at an exercise price equal to $0.26 per share of Common Stock. The public offering price was $0.26 per Unit. The underwriters agreed to purchase 13,250,000 Units at a 7.0% discount to the public offering price. The Company granted the Representatives a 30-day option to purchase up to an additional 1,987,500 shares of common stock and 1,987,500 warrants to cover over-allotments, if any. The gross proceeds from the Offering are approximately $3.445 million, or approximately $3.961 million if the representatives exercise in full their over-allotment option, before deducting underwriting discounts and commissions and other offering expenses. On August 8, 2024, the Representatives partially exercised their over-allotment option to purchase 1,987,500 warrants. The Offering closed on August 9, 2024. Pursuant to the Underwriting Agreement, the Company granted to the representatives, as a portion of the underwriting compensation payable thereunder, Unit Purchase Options to purchase Units equal to an aggregate of 7.0% of the number of Units issued in the Offering at a per Unit exercise price of $0.26, which is equal to the public offering price per Unit sold in the Offering. The Representatives Options are exercisable 180 days after August 7, 2024 and will expire on August 7, 2029. The Units were issued pursuant to a registration statement on Form S-1 (File No. 333-280273), initially filed by the Company with the Securities and Exchange Commission on June 17, 2024, as amended, which was declared effective on August 7, 2024. A final prospectus relating to the Offering was filed with the Commission on August 8, 2024. The Underwriting Agreement contains customary representations, warranties, and covenants by the Company and customary conditions to closing, obligations of the parties and termination provisions. Additionally, under the terms of the Underwriting Agreement, the Company has agreed to indemnify the underwriters for losses, expenses and damages arising out of or in connection with the Offering, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), or contribute to payments the underwriters may be required to make with respect to these liabilities. Pursuant to the Underwriting Agreement, subject to certain exceptions described in the registration statement, the Company and each director and executive officer of the Company have agreed, for a period of three months in the case of the Company and 6 months in the case of the directors and executive officers after the closing of the Offering, not to offer, sell, contract to sell, pledge or otherwise dispose of any shares of the Company’s common stock or securities convertible into common stock, without first obtaining the consent of the Representatives. Pursuant to the Underwriting Agreement, for a period of 12 months after the closing of the Offering, the Representatives will each have a right of first refusal to act lead or joint-lead investment banker, lead or joint-lead book runner and/or lead or joint placement agent, at each of such Representative’s discretion, for each and every future public and private equity, equity-linked or debt (excluding commercial bank debt) offering, including all equity linked financings during such twelve month period, of the Company, or any successor to or subsidiary of the Company on terms customary to the Representatives, excluding any securities issued pursuant to obligations we have outstanding as of the consummation of this Offering. The Company entered into a Warrant Agency Agreement with Equiniti Trust Company, LLC as of August 9, 2024, pursuant to which Equiniti agreed to act as warrant agent with respect to the warrants.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Policies)	9 Months Ended
	Jun. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation
Cash and Cash Equivalents	Cash and Cash Equivalents
Property and Equipment	Property and Equipment
Long-Lived Assets	Long-Lived Assets
Revenue Recognition	Revenue Recognition · identification of the contract, or contracts, with the customer; · identification of the performance obligations in the contract; · determination of the transaction price; · allocation of the transaction price to the performance obligations in the contract; and · recognition of the revenue when, or as, the Company satisfies a performance obligation. Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services.
Research and Development Expenses	Research and Development Expenses
Advertising	Advertising
Fair Value Measurements and Financial Instruments	Fair Value Measurements and Financial Instruments Fair Value Measurement and Disclosures Level 1 – Quoted prices in active markets for identical assets and liabilities; Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and Level 3 – Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of June 30, 2024 and 2023 are based upon the short-term nature of the assets and liabilities. The fair value of the Company’s convertible notes payable are not readily available given the terms and conditions, including the conversion features, are complex. The Company has a money market account which is considered a Level 1 asset. The balance as of June 30, 2024 and September 30, 2023 was $2,103,240 and $7,836,393, respectively. No other assets or liabilities are required to be recorded at fair value on a recurring nature.
Derivative Financial Instruments	Derivative Financial Instruments – The Company determined that the conversion features for purposes of bifurcation within its currently outstanding convertible notes payable were immaterial and there was no derivative liability to be recorded as of June 30, 2024 and 2023.
Stock Based Compensation	Stock Based Compensation
Convertible Securities	Convertible Securities
Net Loss per Share	Net Loss per Share As of June 30, 2024, the Company had 86,368,897 shares of common stock issued and outstanding. As of June 30, 2024, there were options outstanding for the purchase of 30,072,106 shares of the Company’s common stock (including unearned stock option grants totaling 4,179,825 shares related to performance targets), warrants for the purchase of 25,816,476 shares of the Company’s common stock, 8,108,356 shares of the Company’s common stock issuable, collectively, upon the conversion of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and approximately 319,121 shares of the Company’s common stock, collectively, reserved to pay accrued dividends on our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock. In addition, the Company currently has 9,020,264 shares of its common stock at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,761,931 and 4,572,000 shares of its common stock at the current price of $1.00 per share reserved and are issuable upon conversion of convertible debentures of $4,572,000. Further, under the current terms of our Series C Convertible Preferred Stock and Series D Convertible Preferred Stock, and assuming no changes in the ownership thereof, going forward on a quarterly basis the Company will accrete as a preferred dividend the value of approximately 160,000 shares of common stock, which are issuable if such dividends become payable as additional shares of preferred stock, and such preferred stock is then converted into common stock. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the June 30, 2024, calculation of net loss per share because the impact is antidilutive. As of June 30, 2023, the Company had 52,358,463 shares of common stock issued and outstanding. As of June 30, 2023, there were options outstanding for the purchase of 14,506,158 common shares (including unearned stock option grants totaling 3,869,825 shares related to performance targets), warrants for the purchase of 18,856,313 common shares, 8,108,356 shares of our common stock issuable upon the conversion of Series C and Series D Convertible Preferred Stock and approximately 2,920,000 of common shares reserved to pay Series C and D Convertible Preferred Stock dividends. In addition, the Company currently has 9,020,264 common shares at the current price of $0.25 per share reserved and are issuable upon conversion of convertible debentures of $2,255,066. All of the foregoing shares could potentially dilute future earnings per share but are excluded from the June 30, 2023, calculation of net loss per share because their impact is antidilutive.
Comprehensive Loss	Comprehensive loss
Dividend Policy	Dividend Policy
Use of Estimates	Use of Estimates
Recent Accounting Pronouncements	Based on the Company’s review of accounting standard updates recently issued, those standards not yet required to be adopted and proposed standards for the future, the Company does not believe such items are expected to have a significant impact on the Company’s consolidated financial statements.

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Jun. 30, 2024
PROPERTY AND EQUIPMENT
Schedule of Property and equipment	Estimated Useful Lives June 30, 2024 September 30, 2023 Machinery and equipment 2-3 years $ 279,683 $ 213,330 Furniture and fixtures 3 years 21,366 21,366 Less: accumulated depreciation (212,381 ) (153,371 ) $ 88,668 $ 81,325

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Jun. 30, 2024
LEASES
Summary of minimum future lease payments	Year Ended June 30, 2025 $ 126,760 2026 142,755 2027 147,282 2028 12,682 Total remaining payments 429,478 Less imputed interest (43,111 ) Total lease liability $ 386,367

CONVERTIBLE NOTES PAYABLE AND_2

CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Tables)	9 Months Ended
	Jun. 30, 2024
CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE
Schedule of convertible notes payable	June 30, 2024 September 30, 2023 Convertible note- Clayton A. Struve $ 1,301,005 $ 1,301,005 Convertible note- Ronald P. Erickson and affiliates 1,460,926 1,460,926 Lind Global Fund II LP 2,723,145 - $ 5,485,076 $ 2,761,931 Long term $ 945,258 $ - Short term 4,539,818 2,761,931 $ 5,485,076 $ 2,761,931

EQUITY (Tables)

EQUITY (Tables)	9 Months Ended
	Jun. 30, 2024
EQUITY
Schedule of Warrant activity	Weighted Average Exercise Shares Price Outstanding October 1, 2023 20,866,313 $ 1.06 Issued 6,123,648 0.79 Exercised (823,328 ) (0.25 ) Forfeited (350,157 ) (0.42 ) Expired - - Outstanding at end of period 25,816,476 $ 1.03
Schedule of Warrants outstanding and exercisable	Weighted Weighted Average Average Number of Remaining Exercise Shares Warrants Life ( In Years) Price Exercisable 8,619,544 1.54 $ 0.25 8,619,544 6,000,000 4.67 0.80 6,000,000 6,512,207 1.48 1.20-1.85 6,512,207 4,684,725 1.85 2.00-3.00 4,684,725 25,816,476 2.21 $ 1.03 25,816,476
Schedule of weighted average assumptions	Assumptions Dividend yield 0% Expected life 3 years Expected volatility 105% Risk free interest rate 4.32%

STOCK INCENTIVE PLANS (Tables)

STOCK INCENTIVE PLANS (Tables)	9 Months Ended
	Jun. 30, 2024
STOCK INCENTIVE PLANS
Schedule of Stock option activity	Weighted Average Options Exercise Price Outstanding as of September 30, 2023 14,506,158 $ 1.55 Granted 17,410,548 0.31 Exercised - - Forfeitures (1,844,600 ) (1.53 ) Outstanding as of June 30, 2024 30,072,106 $ 0.83
Schedule of Stock options outstanding and exercisable	Weighted Weighted Weighted Average Average Average Range of Number Remaining Life Exercise Price Number Exercise Price Exercise Prices Outstanding In Years Outstanding Exercisable Exercisable $0.25-0.51 16,340,548 4.28 $ 0.29 5,531,545 $ 0.34 $0.62 1,050,000 4.89 0.62 - - $0.88-1.25 2,161,875 2.41 0.15 2,013,125 0.40 $1.28 - 1.67 8,379,683 2.94 1.49 2,444,858 1.47 $1.79-3.67 2,140,000 2.54 2.19 1,093,125 2.16 30,072,106 3.70 $ 0.83 11,082,653 $ 0.72
Schedule of weighted average assumptions relating to stock option grants	Assumptions Dividend yield 0% Expected life 3 years Expected volatility 105% Risk free interest rate 4.16-4.64%

ORGANIZATION (Details Narrative

ORGANIZATION (Details Narrative) - $ / shares	Jun. 30, 2024	Sep. 30, 2023
ORGANIZATION
Authorized shares of capital stock	205,000,000
Authorized shares of capital common stock	200,000,000
Authorized shares of capital stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock share par value	$ 0.001	$ 0.001

LIQUIDITY AND GOING CONCERN (De

LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 27, 2024	Jun. 30, 2024
Cash and cash equivalents		$ 2,129,954
Net working capital		3,987,763
Sell shares of common stock		$ 5,000,000
Stockholder [Member]
Description of securities purchase agreement	the Company (a) entered into a securities purchase agreement with the selling stockholder pursuant to which we may issue to the selling stockholder one or more senior convertible notes in the aggregate principal amount of up $14,400,000 for an aggregate purchase price equal to up to $12,000,000 and common stock purchase warrants and (b) issued a $4,800,000 Note and the warrant to the selling stockholder in exchange for a purchase price of $4,000,000 and net proceeds of $3,805,699

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES ADOPTION OF ACCOUNTING STANDARDS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 18, 2024	Sep. 30, 2023
RESEARCH AND DEVELOPMENT EXPENSES	$ 1,348,985	$ 1,879,519	$ 5,010,618	$ 6,186,039
FDIC insurance	$ 250,000		$ 250,000
Preferred dividend			160,000
Options outstanding	30,072,106		30,072,106
Money market accounts	$ 2,103,240		$ 2,103,240			$ 7,836,393
Common stock shares issued	86,368,897		86,368,897		3,201	80,358,463
Common stock shares outstanding	86,368,897		86,368,897			52,358,463
Issuable upon conversion of convertible debentures	4,572,000		4,572,000
Common shares current price per share	$ 0.31		$ 0.31
Leasehold Improvements
Estimated useful lives of assets			5 years
Minimum
Estimated useful lives of assets			2 years
Maximum
Estimated useful lives of assets			5 years
Stock Option 1 [Member]
Unearned stock option grants			4,179,825	3,869,825
Warrants [Member]
Antidilutive securities			25,816,476
Convertible Preferred Stock
RESEARCH AND DEVELOPMENT EXPENSES	$ 1,348,985	1,879,519	$ 5,010,618	$ 6,186,039
Advertising and marketing costs	$ 40,001	$ 44,252	$ 144,366	$ 149,297
Common stock shares issued	4,572,000		4,572,000			2,920,000
Common stock shares outstanding	9,020,264		9,020,264			9,020,264
Issuable upon conversion of convertible debentures	2,761,931		2,761,931			2,255,066
Warrant purchase				18,856,313
Antidilutive securities			8,108,356	8,108,356
Common shares current price per share	$ 0.25		$ 0.25			$ 0.25

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	9 Months Ended
	Jun. 30, 2024	Sep. 30, 2023
Machinery and equipment	$ 279,683	$ 213,330
Furniture and fixtures	21,366	21,366
Less: accumulated depreciation	(212,381)	(153,371)
Property and equipment, net	$ 88,668	$ 81,325
Furniture and fixtures
Estimated useful life	3 years
Minimum
Estimated useful life	2 years
Maximum
Estimated useful life	3 years

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Depreciation expense	$ 59,009	$ 259,541
Research And Development And Sellings General And Administrative [Mmber]
Depreciation expense	$ 57,092	$ 246,563

LEASES (Details)

LEASES (Details) - USD ($)	Jun. 30, 2024	Sep. 30, 2023
LEASES
2025	$ 126,760
2026	142,755
2027	147,282
2028	12,682
Total Remaining Payments	429,478
Less imputed interest	(43,111)
Total lease liability	$ 386,367	$ 154,797

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2023
LEASES
Lease cost	$ 120,000	$ 203,000
Operating lease liability	386,367		$ 154,797
Right-of-use assets	$ 364,342		$ 145,090
Weighted-average discount rate	7%
weighted average remaining lease term	37 months

CONVERTIBLE NOTES PAYABLE AND_3

CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details) - USD ($)	Jun. 30, 2024	Sep. 30, 2023
Convertible notes, gross	$ 5,485,076	$ 2,761,931
Non-current portion of convertible notes payable, net	945,258	0
Short term	4,539,818	2,761,931
Convertible notes, net	5,485,076	2,761,931
Convertibles Note - Clayton A. Struve
Convertible notes, gross	1,301,005	1,301,005
Convertibles Note - Ronald P. Erickson and Affiliates
Convertible notes, gross	1,460,926	1,460,926
Lind Global Fund II LP
Convertible notes, gross	$ 2,723,145	$ 0

CONVERTIBLE NOTES PAYABLE AND_4

CONVERTIBLE NOTES PAYABLE AND NOTE PAYABLE (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2023	Mar. 16, 2018
Loss on debt extinguishment				$ 230,005
Accrued interest	$ 99,692	$ 99,692		94,062
Amortization of debt	275,830	375,859
Indebtedness		250,000
Market capitalization		15,000,000
Convertible promissory notes	$ 945,258	$ 945,258		0
Description of securities purchase agreement		the Company incurred approximately $994,000 of issuance costs of which $675,971 were allocated to the Note and $318,330 to the Warrant Shares. The amount allocated to the Notes was recorded as debt discount (with an offset to APIC) and is being amortized over the two-year term of the Notes
Description of Note Shares and Warrant Shares upon repayment or conversion of Notes and exercise of Warrants		Issuance of Note Shares and Warrant Shares upon repayment or conversion of Notes and exercise of Warrants is subject to an ownership limitation equal to 4.99% of the Company’s outstanding shares of common stock; provided, that if Lind and its affiliates beneficially own in excess of 4.99% of the Company’s outstanding shares of common stock, then such limitation shall automatically increase to 9.99% so long as Lind and its affiliates own in excess of 4.99% of such common stock (and shall, for the avoidance of doubt, automatically decrease to 4.99% upon Lind and its affiliates ceasing to own in excess of 4.99% of such common stock)
Proceeds from debt offering		$ 3,805,699	$ 0
Issuable upon conversion of Common stock	4,800,000	4,800,000
Warrant Shares		3,000,000
Warrant amount		$ 1,536,743
Convertible Note - Clayton A. Struve
Loss on debt extinguishment				276,860
Accrued interest	$ 116,666	116,666		$ 218,334
Convertible promissory or OID notes	1,301,005	$ 1,301,005
Convertible Note - Ronald P. Erickson and Affiliates
Warrant to purchase common stock shares					1,039,666
Exercise price of warrants					$ 0.50
Convertible promissory notes					$ 1,460,926
Convertible Note - J3E2A2Z Notes
Convertible redeemable promissory note amount					664,233
Convertible redeemable promissory note principal amount					664,233
Convertible Note - J3E2A2Z Account Payable
Convertible redeemable promissory note amount					519,833
Convertible redeemable promissory note principal amount					$ 519,833
Lind Global Fund II LP | February 27, 2024 [Member]
Description of securities purchase agreement		pursuant to which the Company may issue Lind one or more senior convertible notes (the “Notes”) in the aggregate principal amount of up to Fourteen Million Four Hundred Thousand Dollars ($14,400,000) for an aggregate purchase price equal to up to Twelve Million Dollars ($12,000,000) (the “Offering”) and Common Stock purchase warrants and (b) issued to Lind an initial Note with an outstanding principal amount of Four Million Eight Hundred Thousand Dollars ($4,800,000) in exchange for a purchase price of Four Million Dollars ($4,000,000), that is convertible into shares of the Company’s common stock at an initial conversion price of $1.00 per share, subject to adjustment, and an initial Warrant to purchase up to 6,000,000 shares of the Company’s common stock at an initial exercise price of $0.80 per share, subject to adjustment. Warrant Shares issued shall be equal to the applicable funding amount multiplied by 75% and divided by the volume weighted average price of the common stock on the trading date immediately preceding the closing date. The Company issued 3,000,000 to Lind in connection with the $4,000,000 funding amounts
Original Issue Discount	800,000	$ 800,000
Aggregate principal amount	$ 240,000	240,000
Monthly payment		$ 750,000
Cash premium		5%

EQUITY (Details)

EQUITY (Details)	9 Months Ended
	Jun. 30, 2024 $ / shares shares
Shares
Share Outstanding at beginning of period | shares	20,866,313
Issued | shares	6,123,648
Exercised | shares	(823,328)
Forfeited | shares	(350,157)
Expired | shares	0
Outstanding at end of period | shares	25,816,476
Weighted Average Exercise Price:
Outstanding at begin of period | $ / shares	$ 1.06
Weighted Average Exercise Price Issued | $ / shares	0.79
Weighted Average Exercise Price Exercised | $ / shares	(0.25)
Weighted Average Exercise Price Forfeited | $ / shares	(0.42)
Weighted Average Exercise PriceExpired | $ / shares	0
Outstanding at end of period | $ / shares	$ 1.03

EQUITY (Details 1)

EQUITY (Details 1)	9 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of warrants	30,072,106
Weighted average exercise price, outstanding | $ / shares	$ 0.72
Shares exercisable	11,082,653
Warrant Total [Member]
Number of warrants	25,816,476
Weighted average remaining life (years)	2 years 2 months 15 days
Weighted average exercise price, outstanding | $ / shares	$ 1.03
Shares exercisable	25,816,476
Warrant One [Member]
Number of warrants	6,000,000
Weighted average remaining life (years)	4 years 8 months 1 day
Weighted average exercise price, outstanding | $ / shares	$ 0.80
Shares exercisable	6,000,000
Warrant Two [Member]
Number of warrants	6,512,207
Weighted average remaining life (years)	1 year 5 months 23 days
Shares exercisable	6,512,207
Warrant Two [Member] | Minimum
Weighted average exercise price, outstanding | $ / shares	$ 1.20
Warrant Two [Member] | Maximum
Weighted average exercise price, outstanding | $ / shares	$ 1.85
Warrant Three [Member]
Number of warrants	4,684,725
Weighted average remaining life (years)	1 year 10 months 6 days
Shares exercisable	4,684,725
Warrant Three [Member] | Minimum
Weighted average exercise price, outstanding | $ / shares	$ 2
Warrant Three [Member] | Maximum
Weighted average exercise price, outstanding | $ / shares	$ 3
Warrants [Member]
Number of warrants	8,619,544
Weighted average remaining life (years)	1 year 6 months 14 days
Weighted average exercise price, outstanding | $ / shares	$ 0.25
Shares exercisable	8,619,544

EQUITY (Details 2)

EQUITY (Details 2)	9 Months Ended
	Jun. 30, 2024
EQUITY
Dividend yield	0%
Expected life	3 years
Expected volatility	105%
Risk free interest rate	4.32%

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)			1 Months Ended					3 Months Ended	9 Months Ended
	Mar. 07, 2024	Aug. 05, 2016	Jun. 27, 2024	May 24, 2024	Feb. 27, 2024	Oct. 26, 2023	Sep. 29, 2023	Jun. 30, 2024	Jun. 30, 2024	Jun. 18, 2024	Sep. 30, 2023	Aug. 14, 2017
Common stock shares value								$ 86,369	$ 86,369		$ 80,358
Intrinsic value									1,982,495
Automatic conversion of Convertible	the Company issued 102,302 shares of the Company’s common stock at $0.782 with a total value of $80,000 per share related to a debt offering. The $80,000 was recorded as debt issuance costs and is being amortized over the two-year term of the debt
Money warrants									$ 25,816,476
Shrare issued warrant to purchased									9,020,264
Warrant Shares									3,000,000
Cashless warrant exercise				108,500					714,828
Authorized shares of capital stock par value								$ 0.001	$ 0.001		$ 0.001
Preferred stock share par value								$ 0.001	$ 0.001		$ 0.001
Common stock share issued								86,368,897	86,368,897	3,201	80,358,463
Preferred stock shares authorized								5,000,000	5,000,000		5,000,000
Common stock shares authorized								200,000,000	200,000,000		200,000,000
Issuance of common stock for debt payment, amount								$ 240,000
Warrants to Purchase Common Stock [Member]
Cumulative unpaid dividend								$ 800,384	$ 800,384
warrants and received									$ 196,816
Warrant issued to common stock								453,492	453,492
Warrants to purchase common stock								350,157	350,157
Warrants forfeited per share									$ 0.434
Warrants expired per share									$ 0.42
Cashless warrant exercise				108,500
Warrants to Purchase Common Stock One [Member]
Cumulative unpaid dividend								$ 800,384	$ 800,384
Warrants forfeited per share			$ 0.44
Cashless warrant exercise			546,697	108,500					714,828
Share issued price								$ 0.25	$ 0.25
Common stock dividends on Series C and D Preferred Stock, shares									1,402,784
Issuance of common stock for debt payment, amount									$ 240,000
Warrant To Purchase Common Stock Member | Boustead Securities LLC Member
Warrant Shares					300,000
Common stock share issued					6,000,000		123,648
Warrants valued					$ 1,536,743		$ 20,896
Share issued price					$ 0.80		$ 0.25
Common stock dividends on Series C and D Preferred Stock, shares									3,201,534
Authorized Capital Stock [Member]
Authorized shares of capital stock par value								0.001	$ 0.001
Preferred stock share par value								$ 0.001	$ 0.001
Preferred stock shares authorized								5,000,000	5,000,000
Common stock shares authorized								200,000,000	200,000,000
Series C Convertible Preferred Stock designated								30,000	30,000
Series D Convertible Preferred Stock designated								20,000	20,000
Convertible Preferred Stock Series C [Member]
Common stock share issued								82,512,166	82,512,166
Preferred stock shares issued								17,858	17,858
Preferred stock shares outstanding								17,858	17,858
Share issued price								$ 0.25	$ 0.25
Common Stock Offerings
Common stock share issued						883,061
Gross proceeds from sale						$ 203,105
Share issued price						$ 0.25
Convertible Preferred Stock D [Member]
Preferred stock shares issued								10,161	10,161
Preferred stock shares outstanding								10,161	10,161
Share issued price								$ 0.25	$ 0.25
Mr. Struve [Member] | Series C PreferredStockMember
Ownership interest		4.99%
Cumulative Dividend		8%
Purchase preferred stock		$ 1,250,000
Conversion price		$ 0.70
Warrant to acquire common stock shares		1,785,714
Share price		$ 0.25
Authorized shares of capital stock par value								$ 0.001	$ 0.001
Mr. Struve [Member] | Series D Preferred Stock Member
Ownership interest		4.99%							4.99%
Cumulative dividend cash								$ 350,696	$ 350,696
Cumulative Dividend									8%
Purchase preferred stock								$ 750,000	$ 750,000
Adjusted conversion price												$ 0.25
Authorized shares of capital stock par value								$ 0.001	$ 0.001
Preferred stock shares issued								10,161	10,161
Preferred stock shares outstanding								10,161	10,161
Mr. Struve [Member] | Series C and D Preferred Stock [Member]
Ownership interest									4.99%
Cumulative Dividend									4.99%
Number of common stock shares settled									319,121
Common stock shares value								$ 80,000	$ 80,000
Cumulative unpaid dividend								$ 80,000	$ 80,000
Preferred dividend value accrete common stock shares									160,000

STOCK INCENTIVE PLANS (Details)

STOCK INCENTIVE PLANS (Details)	9 Months Ended
	Jun. 30, 2024 $ / shares shares
Shares Granted	6,123,648
Exercised	(823,328)
Forfeited	(350,157)
Share Outstanding at ending of period	30,072,106
Weighted Average Exercise Price Granted | $ / shares	$ 0.79
Weighted Average Exercise Price Exercised | $ / shares	$ (0.25)
Stock Option [Member]
Share Outstanding at beginning of period	14,506,158
Shares Granted	17,410,548
Forfeited	(1,844,600)
Share Outstanding at ending of period	30,072,106
Weighted Average Exercise Price, Outstanding, beginning balance | $ / shares	$ 1.55
Weighted Average Exercise Price Granted | $ / shares	0.31
Weighted Average Exercise Price Forfeitures | $ / shares	(1.53)
Weighted Average Exercise Price, Outstanding, end of period | $ / shares	$ 0.83

STOCK INCENTIVE PLANS (Details

STOCK INCENTIVE PLANS (Details 1)	9 Months Ended
	Jun. 30, 2024 $ / shares shares
Number of outstanding stock options | shares	30,072,106
Weighted average remaining life (years)	3 years 8 months 12 days
Weighted average exercise price outstanding	$ 0.83
Number exercisable | shares	11,082,653
Weighted average exercise price exerciseable	$ 0.72
Stock Options 2 [Member]
Number of outstanding stock options | shares	2,161,875
Weighted average remaining life (years)	2 years 4 months 28 days
Weighted average exercise price outstanding	$ 0.15
Number exercisable | shares	2,013,125
Weighted average exercise price exerciseable	$ 0.40
Stock Options 2 [Member] | Minimum
Range of exercise prices	0.88
Stock Options 2 [Member] | Maximum
Range of exercise prices	$ 1.25
Stock Options 3 [Member]
Number of outstanding stock options | shares	8,379,683
Weighted average remaining life (years)	2 years 11 months 8 days
Weighted average exercise price outstanding	$ 1.49
Number exercisable | shares	2,444,858
Weighted average exercise price exerciseable	$ 1.47
Stock Options 3 [Member] | Minimum
Range of exercise prices	1.28
Stock Options 3 [Member] | Maximum
Range of exercise prices	$ 1.67
Stock Option [Member]
Number of outstanding stock options | shares	16,340,548
Weighted average remaining life (years)	4 years 3 months 10 days
Weighted average exercise price outstanding	$ 0.29
Number exercisable | shares	5,531,545
Weighted average exercise price exerciseable	$ 0.34
Stock Option [Member] | Maximum
Range of exercise prices	0.51
Stock Option [Member] | Minimum
Range of exercise prices	$ 0.25
Stock Option 4 [Member]
Number of outstanding stock options | shares	2,140,000
Weighted average remaining life (years)	2 years 6 months 14 days
Weighted average exercise price outstanding	$ 2.19
Number exercisable | shares	1,093,125
Weighted average exercise price exerciseable	$ 2.16
Stock Option 4 [Member] | Minimum
Range of exercise prices	1.79
Stock Option 4 [Member] | Maximum
Range of exercise prices	3.67
Stock Option 1 [Member]
Range of exercise prices	$ 0.62
Number of outstanding stock options | shares	1,050,000
Weighted average remaining life (years)	4 years 10 months 20 days
Weighted average exercise price outstanding	$ 0.62
Number exercisable | shares	0
Weighted average exercise price exerciseable	$ 0

STOCK INCENTIVE PLANS (Detail_2

STOCK INCENTIVE PLANS (Details 2)	9 Months Ended
	Jun. 30, 2024
Dividend yield	0%
Expected life	3 years
Expected volatility	105%
Risk free interest rate	4.32%
Minimum
Risk free interest rate	4.16%
Maximum
Risk free interest rate	4.64%

STOCK INCENTIVE PLANS (Detail_3

STOCK INCENTIVE PLANS (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jan. 01, 2022	Oct. 15, 2021
Intrinsic value	$ 2,524,513
Stock option grants	30,072,106
Number of common stock authorized shares	30,072,106
Unearned stock option grants	17,410,548
Common shares current price per share	$ 0.31
Stock option grants shares forfeitures	350,157
2021 Equity Incentive Plan [Member]
Number of common stock authorized shares				20,000,000
Number of common stock shares increase			22,000,000
2021 Plan [Member]
Average exercise price	$ 0.83
Purchase of common stock	4,179,825
Compensation expense	$ 2,331,516	$ 2,464,045
Unrecognized costs related party	$ 5,836,061
Expected costs period	3 years 8 months 12 days
Stock Option [Member]
Stock option grants	30,072,106
Weighted Average Exercise Price Forfeitures	$ 1.53
Number of common stock authorized shares	16,340,548
Stock option grants shares forfeitures	1,844,600

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
INCOME TAXES
Provision for income taxes	$ 0	$ 0	$ 0	$ 0
Effective tax rate			0%	0%

SIGNIFICANT AND OTHER TRANSAC_2

SIGNIFICANT AND OTHER TRANSACTIONS WITH RELATED PARTIES (Details Narrative) - $ / shares		9 Months Ended
	Oct. 10, 2023	Jun. 30, 2024
Six Director [Member]
Stock option issued		2,809,817
Share exercise price per shares		$ 0.46
Ronald P Erickson [Member]
Stock option issued	4,640,844
Share exercise price per shares	$ 0.25
Peter J Conley [Member]
Stock option issued	3,001,000
Share exercise price per shares	$ 0.25

COMMITMENTS CONTINGENCIES AND_2

COMMITMENTS CONTINGENCIES AND LEGAL PROCEEDINGS (Details narrative) - USD ($)			1 Months Ended
	Mar. 02, 2024	Apr. 13, 2017	Nov. 22, 2022	Oct. 11, 2021	May 18, 2021
COMMITMENTS AND CONTINGENCIES (Note 11)
Leases, net monthly payment	$ 11,492	$ 2,908	$ 2,250	$ 5,000	$ 8,697
Lease expiry date				Dec. 31, 2023
Lease description	increases at 3% annually after year one. The lease commenced on May 1, 2024 and terminates on July 31, 2027	The Company vacated the office on May 31, 2024	The Company expects to vacate the office on May 31, 2024		the lease was terminated on February 5, 2024

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Aug. 07, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Feb. 27, 2024	Sep. 30, 2023	Sep. 29, 2023
Additional warrants issued	1,987,500
Authorized shares of capital stock par value		$ 0.001		$ 0.001			$ 0.001
Offering expenses		$ 3,835,831	$ 3,239,301	$ 12,036,121	$ 11,693,550
Boustead Securities LLC Member | Warrant To Purchase Common Stock Member
Price per share						$ 0.80		$ 0.25
Subsequent Event [Member]
Additional share purchase	1,987,500
Price per share	$ 0.26
Additional warrants issued	1,987,500
Exercise price	$ 0.26
Stock option grants to employees and directors	13,250,000
Average exercise price	$ 0.26
Gross proceeds	$ 3,445,000
Discount	7%
Offering expenses	$ 3,961,000
Subsequent Event [Member] | Boustead Securities LLC Member | Warrant To Purchase Common Stock Member
Stock option grants to employees and directors	13,250,000
Average exercise price	$ 0.26
Discount	7%
Authorized shares of capital stock par value	$ 0.001